Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or


          Standard; Transfer of Listing.

On December 3, 2019, Sigma Labs, Inc. ("we," "us," "our," "Sigma," or the "Company") appointed Mark Ruport to serve as our Executive Chairman and as a member of our Board of Directors. As a result of Mr. Ruport's appointment as a director, the Company's six-member Board of Directors is comprised of only three independent directors. Accordingly, on January 14, 2020, Sigma received a notice from Nasdaq acknowledging the fact that Sigma does not meet the requirements of Nasdaq's majority of independent director requirement as set forth in Nasdaq Listing Rule 5605(b)(1).

In accordance with Nasdaq Listing Rules, Sigma has 45 calendar days to submit to Nasdaq a plan to regain compliance with Nasdaq Listing Rule 5605(b)(1). If Nasdaq accepts the Company's plan, Nasdaq can grant an extension of up to 180 calendar days from the date of Nasdaq's letter (i.e., until July 12, 2020) to evidence compliance.

Our Board intends to identify candidates and to appoint a new director who satisfies the requirements of Nasdaq Listing Rule 5605(b)(1) prior to the expiration of the applicable compliance and cure periods.

2

© Edgar Online, source Glimpses